Vildagliptin vs sulfonylurea in Indian Muslim diabetes patients fasting during Ramadan

被引:0
作者
Abhijit Shete [1 ]
Aheson Shaikh [2 ]
K Javeed Nayeem [3 ]
Lily Rodrigues [4 ]
Mohamed Sheikamunadeen Sadiq Ali [5 ]
Parag Shah [6 ]
Rajiv Khanna [7 ]
Sarfaraj Majid [8 ]
Sabeer A Rasheed [9 ]
Shehla Shaikh [10 ]
Tawfiqur Rahman [11 ]
机构
[1] Medical Department,Novartis Pharma AG,CH-4002 Basel,Switzerland
[2] Diabetes Care Centre  3. Bibi Ayesha Mili Hospital  4. Suraksha Multi Speciality Hospital 
关键词
Dipeptidyl-peptidase; 4; inhibitors; Fasting hypoglycemia; Sulfonylurea; Type 2 diabetes mellitus; Vildagliptin;
D O I
暂无
中图分类号
R587.1 [糖尿病];
学科分类号
1002 ; 100201 ;
摘要
AIM:To compare the use of vildagliptin and sulfonylurea with or without metformin in Indian Muslim patients with type 2 diabetes mellitus,fasting during Ramadan.METHODS:This was a 4-wk,multicenter,non-interventional,open-label,observational study.Incidence of hypoglycemic events(HEs),adverse events,and changes in glycosylated hemoglobin A1c(HbA1c),fasting plasma glucose,postprandial plasma glucose and body weight were measured pre-and post-Ramadan.RESULTS:Totally,97 patients were recruited and all completed the study(vildagliptin group,n=55;sulfonylurea group,n=42).HEs were reported in low frequencies in both the vildagliptin and the sulfonylurea groups[0 vs 2(4.8%)patients,respectively].Interestingly,HbA1c reduced by-0.43%(-4.71 mmol/mol)in the vildagliptin group[8.75%(72.10 mmol/mol)to8.32%(67.38 mmol/mol),P=0.009]while in the sulfonylurea group there was a small increase by 0.01%[0.08 mmol/mol;8.64%(70.92 mmol/mol)to 8.65%(71.00 mmol/mol),P=0.958].Higher percentage of vildagliptin-treated patients achieved HbA1c<7.0%(<53 mmol/mol)compared with sulfonylurea(16.4%vs4.8%).Mean decrease in the body weight was 1.2 kg and 0.03 kg,respectively(P<0.001).Both treatment groups were well tolerated during Ramadan.CONCLUSION:Vildagliptin is an attractive treatment option for Indian patients with type 2 diabetes mellitus who are fasting during Ramadan.
引用
收藏
页码:358 / 364
页数:7
相关论文
共 15 条
[1]  
Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study[J] . Mohamed Hassanein,Wasim Hanif,Waqar Malik,Ali Kamal,Parnia Geransar,Nicola Lister,Chris Andrews,Anthony Barnett.Current Medical Research & Opinion . 2011 (7)
[2]  
Diabetes and Ramadan: An update On use of glycemic therapies during fasting[J] . Mohamed Ahmed,Tarig Abdu.Annals of Saudi Medicine . 2011 (4)
[3]   Inhibition of DPP-4 with Vildagliptin Improved Insulin Secretion in Response to Oral as well as "Isoglycemic" Intravenous Glucose without Numerically Changing the Incretin Effect in Patients with Type 2 Diabetes [J].
Vardarli, Irfan ;
Nauck, Michael A. ;
Koethe, Lars D. ;
Deacon, Carolyn F. ;
Holst, Jens J. ;
Schweizer, Anja ;
Foley, James E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :945-954
[4]   Recommendations for Management of Diabetes During Ramadan [J].
Al-Arouj, Monira ;
Assaad-Khalil, Samir ;
Buse, John ;
Fahdil, Ibtihal ;
Fahmy, Mohamed ;
Hafez, Sherif ;
Hassanein, Mohamed ;
Ibrahim, Mahmoud Ashraf ;
Kendall, David ;
Kishawi, Suhail ;
Al-Madani, Abdulrazzaq ;
Ben Nakhi, Abdullah ;
Tayeb, Khaled ;
Thomas, Abraham .
DIABETES CARE, 2010, 33 (08) :1895-1902
[5]  
Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study[J] . D. R.Matthews,S.Dejager,B.Ahren,V.Fonseca,E.Ferrannini,A.Couturier,J. E.Foley,B.Zinman.Diabetes, Obesity and Metabolism . 2010 (9)
[6]  
Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience[J] . James Foley.Vascular Health and Risk Management . 2010 (defa)
[7]   Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy [J].
Ahren, Bo ;
Foley, James E. ;
Ferrannini, Ele ;
Matthews, David R. ;
Zinman, Bernard ;
Dejager, Sylvie ;
Fonseca, Vivian A. .
DIABETES CARE, 2010, 33 (04) :730-732
[8]  
Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-na?ve Patients with Type 2 Diabetes[J] . J. E. Foley,S. Sreenan.Horm Metab Res . 2009 (12)
[9]   Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes [J].
Ahren, Bo ;
Schweizer, Anja ;
Dejager, Sylvie ;
Dunning, Beth E. ;
Nilsson, Peter M. ;
Persson, Margaretha ;
Foley, James E. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (04) :1236-1243
[10]  
Efficacy and tolerability of vildagliptin in drug‐na?ve patients with type 2 diabetes and mild hyperglycaemia*[J] . W. A.Scherbaum,A.Schweizer,A.Mari,P. M.Nilsson,G.Lalanne,S.Jauffret,J. E.Foley.Diabetes, Obesity and Metabolism . 2008 (8)